UM
A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice
Cui, Guozhen; Xin, Qiqi; Tseng, Hisa Hui Ling; Hoi, Maggie PuiMan; Wang, Yan; Yang, Binrui; Choi, InLeng; Wang, Yuqiang; Yuan, Rong; Chen, Keji; Cong, Weihong; Lee, Simon MingYuen
2018-08
Source PublicationPHARMACOLOGICAL RESEARCH
ISSN1043-6618
Volume134Pages:109-117
AbstractWe previously reported a novel danshensu derivative (R)-(3,5,6-Trimethylpyrazinyl) methy1-2-acetoxy-3-(3,4-diacetoxyphenyl) propanoate (ADTM) that exhibited promising cardiovascular protective activities, such as antioxidant and antiplatelet activities, as well as arterial relaxation. Particularly, ADTM treatment for 24 h exhibited anti-oxidative activity and effectively protected against acute myocardial infarction (MI) in a rat model. Here, we further investigated the pharmacological actions of 14 days of treatment with ADTM in alleviating and restoring the MI size by stimulating revascularization. The pro-angiogenesis activity of ADTM has been validated in multiple experimental models including MI mouse, zebrafish, human umbilical vein endothelial cells (HUVECs) and A7r5 vascular smooth muscle cells (VSMCs). In addition, the effect of ADTM on L-type Ca2+ current (I-CaL) was determined. We demonstrated that ADTM (12-24 mg/kg) treatment for 14 days significantly decreased myocardial infarct size, increased the blood vessel density compared to vehicle in the myocardial pert infarct area, and ADTM (24 mg/kg) enhanced the serum VEGF level in MI mice (P < 0.05). We also demonstrated that treatment with ADTM at 50-200 mu M rescued chemical-induced blood vessel loss in zebrafish. Although ADTM did not directly promote the features of angiogenesis in HUVECs, ADTM significantly increased VEGF production in a dose-dependent manner in A7r5 cells (P < 0.05). A patch clamp experiment demonstrated that ADTM (200 mu M) inhibited I-CaL at all depolarizing voltages, with > 50% inhibition at + 10 my. Taken together, our results indicated that ADTM served as a Ca2+ current blocker, promoted angiogenesis and reduced experimental myocardial infarct size in mice, probably through stimulation of VEGF production in VSMCs.
KeywordCardioprotection Angiogenesis ADTM Zebrafish VEGF
DOI10.1016/j.phrs.2018.06.005
URLView the original
Indexed BySCI
Language英语
WOS Research AreaPharmacology & Pharmacy
WOS SubjectPharmacology & Pharmacy
WOS IDWOS:000442708500011
PublisherACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:1   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionUniversity of Macau
Recommended Citation
GB/T 7714
Cui, Guozhen,Xin, Qiqi,Tseng, Hisa Hui Ling,et al. A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice[J]. PHARMACOLOGICAL RESEARCH,2018,134:109-117.
APA Cui, Guozhen.,Xin, Qiqi.,Tseng, Hisa Hui Ling.,Hoi, Maggie PuiMan.,Wang, Yan.,...&Lee, Simon MingYuen.(2018).A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice.PHARMACOLOGICAL RESEARCH,134,109-117.
MLA Cui, Guozhen,et al."A novel Ca2+ current blocker promotes angiogenesis and cardiac healing after experimental myocardial infarction in mice".PHARMACOLOGICAL RESEARCH 134(2018):109-117.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Cui, Guozhen]'s Articles
[Xin, Qiqi]'s Articles
[Tseng, Hisa Hui Ling]'s Articles
Baidu academic
Similar articles in Baidu academic
[Cui, Guozhen]'s Articles
[Xin, Qiqi]'s Articles
[Tseng, Hisa Hui Ling]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Cui, Guozhen]'s Articles
[Xin, Qiqi]'s Articles
[Tseng, Hisa Hui Ling]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Cui-2018-A-novel-ca---current-blocker-promot.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.